Navigation Links
Tablet is better all round for cancer patients
Date:10/8/2007

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

Standard chemotherapy can be incredibly disruptive to peoples lives, said Prof Professor Chris Twelves of the University of Leeds, who led the research. Patients visit hospital five days a week for the injections and then have three weeks off before returning to hospital for the next course and the side effects can be unpleasant.

The oral chemotherapy drug Xeloda (capecitabine) offers fewer side-effects and less time in hospital and the trial has shown that patients given the drug were at least as likely to be alive and free of their disease as those on standard chemotherapy (the Mayo Clinic regimen).

The research showed that about 71 percent of patients given Xeloda were still alive after five years, compared to 68 percent of patients treated with standard chemotherapy injections.

Prof Twelvess study followed 1,987 patients who had undergone colon cancer surgery. It found that patients treated with Xeloda spent 85 percent less time with their doctor or at the hospital, and experienced fewer side effects. The new results, showing patients five-year survival rates, confirm the effectiveness of the treatment.

We now have long-term evidence now that clearly supports Xeloda's superiority over the Mayo Clinic regimen, said Prof Twelves. There is now no reason why we should ask colon cancer patients to endure the burdens associated with that older treatment.


'/>"/>
Contact: Simon Jenkins
J.Hicks@leeds.ac.uk
0044-011-334-34031
University of Leeds
Source:Eurekalert

Page: 1

Related medicine news :

1. Clarithromycin tablets to be launched in India soon
2. Cadila gets US FDA approval for Promethazine tablets
3. Say no to detox tablets
4. Manic Ecstasy: Man gets Into a Frenzy after a Record Consumption of 40,000 ecstasy tablets
5. Three Arrested For Illegal Export Of Ephedrine Tablets
6. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
7. Cadila Gets Tentative USFDA Nod For Pravastatin Sodium Tablets
8. Lupin Gets USFDA Approval For Quinapril Tablets
9. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
10. Aurobindo Gets USFDA Approval for Didanosine Chewable Tablets
11. Ranbaxy Launches Clarithromycin, Terbinafine Tablets in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... MANDEVILLE, La. (PRWEB) , ... February 18, 2017 ... ... Network released today provides the latest information and contact points to easily connect ... including home care, assisted living, and elder-care funding. It also conveys material on ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data ... has introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. ... EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network ... prescribing of controlled and non-controlled substances plus the ability to manage orders on ... United States now accept electronic prescriptions, according to the Office of the National ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... February 17, ... ... Devices, Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. ... , Do manufacturers distinguish between corrective action (CA) and preventive action ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Company plc (NYSE, TASE: PRGO) today announced it has received ... hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 ... homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 ... adults and children 6 years of age and older. Annual ... $16 million.   ...
(Date:2/17/2017)... Feb. 17, 2017   FormFast , the leader ... new partnership with Engage , one of the ... . FormFast will serve as the forms automation ... with MEDITECH .  FormFast is ... to complement and enhance the electronic health record. FormFast,s ...
(Date:2/16/2017)... Feb. 16, 2017 Absorption Systems, a global ... devices, is pleased to announce that its Chief Operating ... as a winner of the 2017 Executive Management Award. ... and recognizes driven executives for their creative management vision, ... awards ceremony and celebration is on March 8, 2017 ...
Breaking Medicine Technology: